Testing a new prostate cancer blood test in diverse groups
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new blood test (PRODICT®) to see how well it works for finding prostate cancer in men from different ethnic backgrounds. It aims to make sure the test is accurate and fair for everyone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 to 55 years old.
- You were born male (this study includes people with a prostate).
- You have a background that is Black African or Caribbean, White European, or South/East Asian (and all 4 of your grandparents share that ancestry).
- You haven't been diagnosed with prostate cancer before.
- You haven't had a prostate biopsy in the last year that found no cancer.
- You don't have a serious psychological condition that might get worse if you join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how inherited risk (family history or gene findings) relates to screening and treatment for prostate cancer. If you qualify, you may be offered prostate screening tests and follow-up to see how well risk information predicts next steps.
This trial studies whether a risk assessment can better predict who actually has prostate cancer based on information collected around the biopsy. It may help doctors decide what biopsy findings mean for people with certain PSA (a blood test) results.
This study compares how well a doctor’s MRI reading (the PI-RADS score) and a computer AI tool detect prostate cancer. It may help improve how men get targeted biopsies and avoid missing important cancers.
This study checks whether certain blood markers can help predict how well people with prostate cancer will respond to therapy. It may help doctors choose the most effective treatment sooner by using information from your blood.
This study is testing a new approach to prostate biopsy that takes samples from around a suspicious area seen on MRI. It aims to see if this method can better detect prostate cancer compared to standard biopsy.
This trial studies a blood test that looks for tumor DNA in men with high-risk or advanced prostate cancer. It may help doctors understand the cancer better and guide treatment decisions.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.